

Shahryar Pourfarzam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12144965/publications.pdf>

Version: 2024-02-01

21
papers

397
citations

840119

11
h-index

752256

20
g-index

21
all docs

21
docs citations

21
times ranked

294
citing authors

#	ARTICLE	IF	CITATIONS
1	Alteration in inflammatory mediators in seriously eye-injured war veterans, long-term after sulfur mustard exposure. <i>International Immunopharmacology</i> , 2020, 80, 105897.	1.7	6
2	Serum and sputum levels of IL-17, IL-21, TNF α and mRNA expression of IL-17 in sulfur mustard lung tissue with long term pulmonary complications (28 years after sulfur mustard exposure). <i>International Immunopharmacology</i> , 2019, 76, 105828.	1.7	3
3	Evaluation of Association Between the Serum Levels of MMP-9 and MMP-9/TIMPs With Soluble Forms of Selectins and Itching Induced by Sulfur Mustard. <i>Iranian Journal of Pathology</i> , 2017, 12, 257-264.	0.2	0
4	Correlation between MMP-9 and MMP-9/ TIMPs Complex with Pulmonary Function in Sulfur Mustard Exposed Civilians: Sardasht-Iran Cohort Study. <i>Archives of Iranian Medicine</i> , 2017, 20, 74-82.	0.2	8
5	Association of Macrophage Activating Syndrome with Castleman's Syndrome in Systemic Lupus Erythematosus. <i>Iranian Journal of Pathology</i> , 2016, 11, 265-271.	0.2	6
6	Fibrinogen and inflammatory cytokines in spontaneous sputum of sulfur-mustard-exposed civilians "Sardasht-Iran Cohort Study. <i>International Immunopharmacology</i> , 2013, 17, 968-973.	1.7	14
7	Salivary levels of secretory IgA, C5a and alpha 1-antitrypsin in sulfur mustard exposed patients 20years after the exposure, Sardasht-Iran Cohort Study (SICS). <i>International Immunopharmacology</i> , 2013, 17, 952-957.	1.7	3
8	Chemokines, MMP-9 and PMN elastase in spontaneous sputum of sulfur mustard exposed civilians: Sardasht-Iran Cohort Study. <i>International Immunopharmacology</i> , 2013, 17, 958-963.	1.7	13
9	A clinicopathological approach to sulfur mustard-induced organ complications: a major review. <i>Cutaneous and Ocular Toxicology</i> , 2013, 32, 304-324.	0.5	39
10	Are serum levels of immunoglobulin classes and IgG subclasses involved in delayed pulmonary complications induced by sulfur mustard? Sardasht-Iran Cohort Study. <i>International Immunopharmacology</i> , 2013, 17, 936-943.	1.7	7
11	Long-term hematological consequences of sulfur mustard on civilians of Sardasht 20 years after exposure. <i>Toxin Reviews</i> , 2009, 28, 39-43.	1.5	16
12	Long-term cardiovascular symptoms and signs in mustard gas victims. <i>Toxin Reviews</i> , 2009, 28, 30-33.	1.5	4
13	Serum soluble Fas ligand and nitric oxide in long-term pulmonary complications induced by sulfur mustard: Sardasht-Iran Cohort Study. <i>International Immunopharmacology</i> , 2009, 9, 1489-1493.	1.7	18
14	Evaluation of relationship between the serum levels of inflammatory mediators and ocular injuries induced by sulfur mustard: Sardasht-Iran Cohort Study. <i>International Immunopharmacology</i> , 2009, 9, 1494-1498.	1.7	25
15	Serum levels of GM-CSF 20years after sulfur mustard exposure: Sardasht-Iran Cohort Study. <i>International Immunopharmacology</i> , 2009, 9, 1499-1503.	1.7	9
16	Serum levels of IL-8 and IL-6 in the long term pulmonary complications induced by sulfur mustard: Sardasht-Iran Cohort Study. <i>International Immunopharmacology</i> , 2009, 9, 1482-1488.	1.7	57
17	Long-term pulmonary complications in sulfur mustard victims of Sardasht, Iran. <i>Toxin Reviews</i> , 2009, 28, 8-13.	1.5	22
18	Long-term health status 20 years after sulfur mustard exposure. <i>Toxin Reviews</i> , 2009, 28, 3-7.	1.5	12

#	ARTICLE	IF	CITATIONS
19	Long-term rheumatologic complications of sulfur mustard in victims of Sardasht, Iran. <i>Toxin Reviews</i> , 2009, 28, 34-38.	1.5	5
20	Sardasht-Iran cohort study of chemical warfare victims: design and methods. <i>Archives of Iranian Medicine</i> , 2009, 12, 5-14.	0.2	76
21	Long-term ocular complications of sulfur mustard in the civilian victims of sardasht, iran. <i>Cutaneous and Ocular Toxicology</i> , 2008, 27, 317-326.	0.5	54